In this Issue
Examining lessons learned as new results emerge across the spectrum of SFA therapies.
Chief Medical Editor’s Page
By John R. Laird, MD
The current data and future directions of SFA stenting technology.
By Ehrin J. Armstrong, MD, John R. Laird, MD
New data and specialized technologies are emerging, but where do we still need information?
By Lawrence A. Garcia, MD
A stentless technology is an attractive option if it achieves at least as good acute and long-term results as current devices in the femoropopliteal artery.
By Thomas Zeller, MD
Insights into the clinical safety and efficacy of this emerging technology.
By Maxwell E. Afari, MD, and Juan F. Granada, MD, FACC
Featuring Gary M. Ansel, MD; Bruce H. Gray, DO, MSVM, FSCAI; John H. Rundback, MD; and Evan Lipsitz, MD
Some healthy introspection based on the current literature.
By Eanas S. Yassa, MD, and Joseph V. Lombardi, MD
The shift to endovascular therapy continues to grow. A case review and discussion.
By Dorian J. deFreitas, MD, and Joseph J. Ricotta II, MD, MS
Endovascular management of a renal artery aneurysm with large arteriovenous fistula and giant venous aneurysm.
By Rupal Bandi, MD, and Yun Robert Sheu, MD, MS
A leading TASC author discusses the value and challenges in establishing guidelines, goals for TASC III, exercise therapy, and the FDA’s advisory committee processes.